CRACking pancreatitis

The handful of companies pursuing CRAC inhibitors for immunological disorders have a new indication to consider-acute pancreatitis. New findings from Cardiff University1 show that the target plays a central role in the painful and potentially life-threatening condition for which there are no FDA-approved, disease-modifying therapies.

Binge drinking can trigger acute pancreatitis, in which excessive release of pancreatic enzymes leads to pain, inflammation and damage to pancreatic tissue.

Treatment focuses on alleviating pain and inflammation or on managing rare metabolic conditions that bring on bouts of the disorder independently of binge drinking. For example, Glybera alipogene tiparvovec (AMT-011), a gene therapy from uniQure B.V., is approved in the EU to treat lipoprotein lipase (LPL) deficiency, a hereditary condition that leads to acute, recurring pancreatitis.

The Cardiff team, led by professor and director of biosciences Ole Petersen, now has evidence in

Read the full 1369 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers